Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : HVH-2930
Catalog No.: PC-22212Not For Human Use, Lab Use Only.
HVH-2930 is a specfiic small molecule C-terminal HSP90 inhibitor with SPR KD of 97.2 uM (HSP90α), reduces cell viability and induces apoptosis in HER2-positive breast cancer cells, targets the C-terminal HSP90 without inducing heat shock response (HSR).
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
HVH-2930 is a specfiic small molecule C-terminal HSP90 inhibitor with SPR KD of 97.2 uM (HSP90α), reduces cell viability and induces apoptosis in HER2-positive breast cancer cells, targets the C-terminal HSP90 without inducing heat shock response (HSR).
HVH-2930 effectively inhibited the activity of C-terminal HSP90 by competitively interfering with the binding capability of the co-chaperone PPID, similar to the well-characterized C-terminal HSP90 inhibitor novobiocin.
HVH-2930 dose-dependently reduces cell viability in both trastuzumab-sensitive [BT474 and SKBR3] and -resistant cells [JIMT-1 and MDA-MB453] with IC50 of 6.86 μM, 5.13 μM, 3.94 and 3.93 μM, respectively.
HVH-2930 shows much more higher affinity than novobiocin.
HVH-2930 is a potent C-terminal hHSP90 inhibitor because it not only inhibits the binding of ATP but also stabilizes its open conformation.
HVH-2930-induced apoptosis is accompanied by activation of effector caspases and mitochondrial dysfunction.
HVH-2930 suppresses the HER2 signaling pathway by degrading HSP90 clients.
HVH-2930 inhibits tumor growth of trastuzumab-resistant JIMT-1 xenografts, attenuates CSC-like properties in HER2-positive breast cancer cells.
| M.Wt | 488.63 | |
| Formula | C29H36N4O3 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Minsu Park, et al. Theranostics. 2024 Mar 31;14(6):2442-2463
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
